This prototype is currently only available on desktop
Best regards, Odin IR team

Newsroom

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Erster Börsengang einer Beteiligung dürfte Xlife kräftig Schub geben

Xlife Sciences Aktie: Segmentwechsel auf Generalversammlung 26. Juni

Xlife Sciences: Portfolio company VERAXA Biotech begins trading on NASDAQ

Landsteiner: Built for Every Terrain

Xlife-Portfolio wird mit bis zu 754,7 Mio. Fr. bewertet

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year.

Xlife Sciences Aktie: Zukunftsperspektiven stimmen!

Xlife Sciences AG achieves breakthrough in the early detection of Alzheimer's disease and unlocks significant market potential

The Swiss bio incubator Xlife Sciences to propel Korean biotech IPOs within five years

Xlife Sciences mit fulminantem Börsendebut am Sparks-Segment

Erster Börsengang einer Beteiligung dürfte Xlife kräftig Schub geben

Xlife Sciences Aktie: Segmentwechsel auf Generalversammlung 26. Juni

Xlife Sciences: Portfolio company VERAXA Biotech begins trading on NASDAQ

Xlife-Portfolio wird mit bis zu 754,7 Mio. Fr. bewertet

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year.

Xlife Sciences Aktie: Zukunftsperspektiven stimmen!

Xlife Sciences AG achieves breakthrough in the early detection of Alzheimer's disease and unlocks significant market potential

The Swiss bio incubator Xlife Sciences to propel Korean biotech IPOs within five years

Xlife Sciences mit fulminantem Börsendebut am Sparks-Segment

Erster Börsengang einer Beteiligung dürfte Xlife kräftig Schub geben

Xlife Sciences: Portfolio company VERAXA Biotech begins trading on NASDAQ

Landsteiner: Built for Every Terrain

Xlife-Portfolio wird mit bis zu 754,7 Mio. Fr. bewertet

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year.

Xlife Sciences AG achieves breakthrough in the early detection of Alzheimer's disease and unlocks significant market potential

The Swiss bio incubator Xlife Sciences to propel Korean biotech IPOs within five years

Xlife-Portfolio wird mit bis zu 754,7 Mio. Fr. bewertet

Xlife Sciences Aktie: Zukunftsperspektiven stimmen!

Xlife-Portfolio wird mit bis zu 754,7 Mio. Fr. bewertet

Erster Börsengang einer Beteiligung dürfte Xlife kräftig Schub geben

Xlife Sciences: Portfolio company VERAXA Biotech begins trading on NASDAQ

Landsteiner: Built for Every Terrain

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year.

Xlife Sciences AG achieves breakthrough in the early detection of Alzheimer's disease and unlocks significant market potential

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Continue learning

Download latest report

Valuation Report 2025

Laboratory microscope head and turret in soft focus beside a teal gradient background panel

Download latest report

Valuation Report 2025

Laboratory microscope head and turret in soft focus beside a teal gradient background panel